Correspondence  |   October 2017
Clarification: Current Status of Neuromuscular Reversal and Monitoring, Challenges and Opportunities
Author Notes
  • GE Healthcare, Madison, Wisconsin (E.C.H.). Elise.Hyman@ge.com
  • (Accepted for publication June 22, 2017.)
    (Accepted for publication June 22, 2017.)×
Article Information
Correspondence
Correspondence   |   October 2017
Clarification: Current Status of Neuromuscular Reversal and Monitoring, Challenges and Opportunities
Anesthesiology 10 2017, Vol.127, 730. doi:10.1097/ALN.0000000000001795
Anesthesiology 10 2017, Vol.127, 730. doi:10.1097/ALN.0000000000001795
We are writing to clarify certain statements and information provided in a recent review of neuromuscular reversal and monitoring.1 
The article stated that, “The GE Healthcare E-NMT-01 module was recalled by the FDA in 2014.” To clarify, GE Healthcare initiated the recall voluntarily, and the announcement appeared on the U.S. Food and Drug Administration Web site. This voluntary recall action entailed technology correction and replacement of all modules in the field. It was completed September 28, 2015. The GE Healthcare NeuroMuscular Transmission (NMT) module is commercially available. Additional information is available on the U.S. Food and Drug Administration Web site.2 
First Page Preview
First page PDF preview
First page PDF preview ×
View Large